Biomarker identified in relation to drug response in refractory urothelial cancer
The antiangiogenic drug pazopanib has demonstrated clinically meaningful activity in patients with refractory urothelial cancer, according to results presented at the AACR Annual Meeting 2012, held here March 31 - April 4. ...
Apr 1, 2012
0
0